Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Moderna, Inc.

NASDAQ

Market Cap.

63.85B

Avg. Volume

3.91M

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Moderna, Inc.!

Still processing it, give me a bit more time...

Moderna, Inc. News

Moderna, Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Website screenshot
HealthcareBiotechnology
modernatx.com

About Moderna, Inc.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna, Inc. Earnings & Revenue

Moderna, Inc. Financials

Table Compare

Compare MRNA metrics with:

   

Earnings & Growth

MRNA

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

MRNA

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

MRNA

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

MRNA

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Moderna, Inc. Income

Moderna, Inc. Balance Sheet

Moderna, Inc. Cash Flow

Moderna, Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Sell
Return on EquitySell
Return on AssetsSell
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Moderna, Inc. Executives

NameRole
Mr. Stephane BancelChief Executive Officer & Director
Dr. Stephen Hoge M.D.President
Mr. James M. MockChief Financial Officer
Ms. Shannon Thyme KlingerChief Legal Officer & Corporate Secretary
Colleen HusseySenior Director of Corporate Communications
NameRoleGenderDate of BirthPay
Mr. Stephane BancelChief Executive Officer & DirectorMale19734.55M
Dr. Stephen Hoge M.D.President19771.92M
Mr. James M. MockChief Financial OfficerMale19771.4M
Ms. Shannon Thyme KlingerChief Legal Officer & Corporate SecretaryFemale19711.39M
Colleen HusseySenior Director of Corporate Communications

--

Moderna, Inc. Insider Trades

Date22 May
NameAFEYAN NOUBAR
RoleDirector
TransactionDisposed
TypeS-Sale
Shares100
Date22 May
NameAFEYAN NOUBAR
RoleDirector
TransactionDisposed
TypeS-Sale
Shares200
Date22 May
NameAFEYAN NOUBAR
RoleDirector
TransactionDisposed
TypeS-Sale
Shares100
Date22 May
NameAFEYAN NOUBAR
RoleDirector
TransactionDisposed
TypeS-Sale
Shares300
Date22 May
NameAFEYAN NOUBAR
RoleDirector
TransactionDisposed
TypeS-Sale
Shares600
DateNameRoleTransactionTypeShares
22 MayAFEYAN NOUBARDirectorDisposedS-Sale100
22 MayAFEYAN NOUBARDirectorDisposedS-Sale200
22 MayAFEYAN NOUBARDirectorDisposedS-Sale100
22 MayAFEYAN NOUBARDirectorDisposedS-Sale300
22 MayAFEYAN NOUBARDirectorDisposedS-Sale600

Discover More

Streamlined Academy

Moderna, Inc.

NASDAQ

Market Cap.

63.85B

Avg. Volume

3.91M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Moderna, Inc. News

Moderna, Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Moderna, Inc. Earnings & Revenue

Moderna, Inc. Income

Moderna, Inc. Balance Sheet

Moderna, Inc. Cash Flow

Moderna, Inc. Financials Over Time

Moderna, Inc. Executives

NameRole
Mr. Stephane BancelChief Executive Officer & Director
Dr. Stephen Hoge M.D.President
Mr. James M. MockChief Financial Officer
Ms. Shannon Thyme KlingerChief Legal Officer & Corporate Secretary
Colleen HusseySenior Director of Corporate Communications
NameRoleGenderDate of BirthPay
Mr. Stephane BancelChief Executive Officer & DirectorMale19734.55M
Dr. Stephen Hoge M.D.President19771.92M
Mr. James M. MockChief Financial OfficerMale19771.4M
Ms. Shannon Thyme KlingerChief Legal Officer & Corporate SecretaryFemale19711.39M
Colleen HusseySenior Director of Corporate Communications

--

Moderna, Inc. Insider Trades

Date22 May
NameAFEYAN NOUBAR
RoleDirector
TransactionDisposed
TypeS-Sale
Shares100
Date22 May
NameAFEYAN NOUBAR
RoleDirector
TransactionDisposed
TypeS-Sale
Shares200
Date22 May
NameAFEYAN NOUBAR
RoleDirector
TransactionDisposed
TypeS-Sale
Shares100
Date22 May
NameAFEYAN NOUBAR
RoleDirector
TransactionDisposed
TypeS-Sale
Shares300
Date22 May
NameAFEYAN NOUBAR
RoleDirector
TransactionDisposed
TypeS-Sale
Shares600
DateNameRoleTransactionTypeShares
22 MayAFEYAN NOUBARDirectorDisposedS-Sale100
22 MayAFEYAN NOUBARDirectorDisposedS-Sale200
22 MayAFEYAN NOUBARDirectorDisposedS-Sale100
22 MayAFEYAN NOUBARDirectorDisposedS-Sale300
22 MayAFEYAN NOUBARDirectorDisposedS-Sale600

Streamlined Academy

Website screenshot
HealthcareBiotechnology
modernatx.com

About Moderna, Inc.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Moderna, Inc.!

Still processing it, give me a bit more time...

Moderna, Inc. Financials

Table Compare

Compare MRNA metrics with:

   

Earnings & Growth

MRNA

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

MRNA

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

MRNA

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

MRNA

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Moderna, Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Sell
Return on EquitySell
Return on AssetsSell
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More